Cost-Effectiveness of Combination of Baricitinib and Remdesivir in Hospitalized Patients with COVID-19 in the United States: A Modelling Study

INTRODUCTION: Baricitinib–remdesivir (BARI-REM) combination is superior to remdesivir (REM) in reducing recovery time and accelerating clinical improvement among hospitalized patients with coronavirus disease 2019 (COVID-19), specifically those receiving high-flow oxygen/noninvasive ventilation. Her...

Descripción completa

Detalles Bibliográficos
Autores principales: Kelton, Kari, Klein, Tim, Murphy, Dan, Belger, Mark, Hille, Erik, McCollam, Patrick L., Spiro, Theodore, Burge, Russel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8606629/
https://www.ncbi.nlm.nih.gov/pubmed/34807369
http://dx.doi.org/10.1007/s12325-021-01982-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8606629/
https://www.ncbi.nlm.nih.gov/pubmed/34807369
http://dx.doi.org/10.1007/s12325-021-01982-6

Ejemplares similares